Patents by Inventor Nigel Bunnett

Nigel Bunnett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL ACTIVITY-BASED PROBES FOR NEUTROPHIL ELASTASE AND THEIR USE
    Publication number: 20230140838
    Abstract: The present invention relates to compounds of formula I, wherein D is a detectable moiety, or salts thereof, which can be used as activity-based probes for neutrophil elastase, as well as to methods for detecting neutrophil elastase (NE) activity in a tissue sample lysate, and related diagnostic methods using compounds of formula I.
    Type: Application
    Filed: December 20, 2019
    Publication date: May 4, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Laura EDGINGTON-MITCHELL, Bethany M. ANDERSON, Daniel P. POOLE, Luigi AURELIO, Paulina KASPERKIEWICZ, Marcin DRAG, Nigel BUNNETT
  • NOVEL ACTIVITY-BASED PROBES FOR NEUTROPHIL ELASTASE AND THEIR USE
    Publication number: 20220050107
    Abstract: The present invention relates to compounds of formula I, wherein D is a detectable moiety, or salts thereof, which can be used as activity-based probes for neutrophil elastase, as well as to methods for detecting neutrophil elastase (NE) activity in a tissue sample lysate, and related diagnostic methods using compounds of formula I.
    Type: Application
    Filed: December 12, 2019
    Publication date: February 17, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Laura EDGINGTON-MITCHELL, Bethany M. ANDERSON, Daniel P. POOLE, Luigi AURELIO, Paulina KASPERKIEWICZ, Marcin DRAG, Nigel BUNNETT
  • NANOPARTICLE ENCAPSULATION TO TARGET G PROTEIN-COUPLED RECEPTORS IN ENDOSOMES
    Publication number: 20220031849
    Abstract: The present invention relates to methods for modulating endosomal GPCR signaling. In particular, the present invention relates to use of polymeric nanoparticles for the targeted delivery of hydrophobic modulators of endosomal GPCRs and their use in the treatment of associated diseases and disorder.
    Type: Application
    Filed: October 22, 2019
    Publication date: February 3, 2022
    Inventors: Nigel Bunnett, Thomas Davis, Michael Whittaker, Nicholas Veldhuis
  • INHIBITORS OF BETA-ARRESTIN-NEUROKININ 1 RECEPTOR INTERACTIONS FOR THE TREATMENT OF PAIN
    Publication number: 20200206299
    Abstract: The present invention relates to compounds and their uses. In particular, to compounds that inhibit the interaction between ?-arrestin and the intracellular C-terminus of the activated NK1R and their use in the treatment of pain.
    Type: Application
    Filed: February 23, 2017
    Publication date: July 2, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventor: Nigel Bunnett
  • TREATMENT OF PAIN
    Publication number: 20190298743
    Abstract: The present invention relates to compounds and their uses. In particular, to compounds that inhibit endosomal protease-activated receptor-2 (PAR2) signaling and their use in the treatment of pain.
    Type: Application
    Filed: May 19, 2017
    Publication date: October 3, 2019
    Applicant: Takeda Pharmaceutical Company Limited
    Inventor: Nigel Bunnett